Horowitz Richard I, Freeman Phyllis R
Member, HHS Babesia and Tick-borne Pathogens Subcommittee, Washington, DC 20201, USA.
Hudson Valley Healing Arts Center, Hyde Park, NY 12538, USA.
Antibiotics (Basel). 2020 Oct 22;9(11):725. doi: 10.3390/antibiotics9110725.
Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double-dose dapsone combination therapy (DDD CT) for a total of 7-8 weeks. At the completion of therapy, all three patients' major Lyme symptoms remained in remission for a period of 25-30 months. A retrospective chart review of 37 additional patients undergoing DDD CT therapy (40 patients in total) was also performed, which demonstrated tick-borne symptom improvements in 98% of patients, with 45% remaining in remission for 1 year or longer. In conclusion, double-dose dapsone therapy could represent a novel and effective anti-infective strategy in chronic Lyme disease/ post-treatment Lyme disease syndrome (PTLDS), especially in those individuals who have failed regular dose dapsone combination therapy (DDS CT) or standard antibiotic protocols. A randomized, blinded, placebo-controlled trial is warranted to evaluate the efficacy of DDD CT in those individuals with chronic Lyme disease/PTLDS.
三名患有复发性和缓解性莱姆病多年且伴有相关合并感染的患者，尽管接受了长期抗生素治疗，但仍分别接受了为期7至8周的双倍剂量氨苯砜联合疗法（DDD CT）。治疗结束时，所有三名患者的主要莱姆病症状均持续缓解了25至30个月。还对另外37名接受DDD CT治疗的患者（总共40名患者）进行了回顾性病历审查，结果显示98%的患者蜱传症状有所改善，其中45%的患者缓解期持续了1年或更长时间。总之，双倍剂量氨苯砜疗法可能是慢性莱姆病/治疗后莱姆病综合征（PTLDS）一种新的有效抗感染策略，尤其是对于那些常规剂量氨苯砜联合疗法（DDS CT）或标准抗生素方案治疗失败的个体。有必要进行一项随机、双盲、安慰剂对照试验，以评估DDD CT对那些患有慢性莱姆病/PTLDS个体的疗效。
